Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease

John D. Clarke, Petr Novak, April D. Lake, Rhiannon N. Hardwick, Nathan J Cherrington

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background & Aims: N-linked glycosylation of proteins is critical for proper protein folding and trafficking to the plasma membrane. Drug transporters are one class of proteins that have reduced function when glycosylation is impaired. N-linked glycosylation of plasma proteins has also been investigated as a biomarker for several liver diseases, including non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to assess the transcriptomic expression of genes involved in protein processing and glycosylation, and to determine the glycosylation status of key drug transporters during human NAFLD progression. Methods: Human liver samples diagnosed as healthy, steatosis, and non-alcoholic steatohepatitis (NASH) were analysed for gene expression of glycosylation-related genes and for protein glycosylation using immunoblot. Results: Genes involved in protein processing in the ER and biosynthesis of N-glycans were significantly enriched for down-regulation in NAFLD progression. Included in the down regulated N-glycan biosynthesis category were genes involved in the oligosaccharyltransferase complex, N-glycan quality control, N-glycan precursor biosynthesis, N-glycan trimming to the core, and N-glycan extension from the core. N-glycan degradation genes were unaltered in the progression to NASH. Immunoblot analysis of the uptake transporters organic anion transporting polypeptide-1B1 (OATP1B1), OATP1B3, OATP2B1, and Sodium/Taurocholate Co-transporting Polypeptide (NTCP) and the efflux transporter multidrug resistance-associated protein 2 (MRP2) demonstrated a significant loss of glycosylation following the progression to NASH. Conclusions: These data suggest that the loss of glycosylation of key uptake and efflux transporters in humans NASH may influence transporter function and contribute to altered drug disposition observed in NASH.

Original languageEnglish (US)
Pages (from-to)1074-1081
Number of pages8
JournalLiver International
Volume37
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Glycosylation
Polysaccharides
Fatty Liver
Disease Progression
Organic Anion Transporters
Pharmaceutical Preparations
Genes
Gene Expression
Non-alcoholic Fatty Liver Disease
Taurocholic Acid
Peptides
Proteins
Protein Folding
Protein Transport
Quality Control
Liver Diseases
Blood Proteins
Down-Regulation
Biomarkers
Cell Membrane

Keywords

  • drug transporters
  • hepatobiliary drug disposition
  • N-linked glycosylation
  • Non-alcoholic steatohepatitis

ASJC Scopus subject areas

  • Hepatology

Cite this

Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. / Clarke, John D.; Novak, Petr; Lake, April D.; Hardwick, Rhiannon N.; Cherrington, Nathan J.

In: Liver International, Vol. 37, No. 7, 01.07.2017, p. 1074-1081.

Research output: Contribution to journalArticle

Clarke, John D. ; Novak, Petr ; Lake, April D. ; Hardwick, Rhiannon N. ; Cherrington, Nathan J. / Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. In: Liver International. 2017 ; Vol. 37, No. 7. pp. 1074-1081.
@article{71b2562cd2aa494585a8b67d016864f1,
title = "Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease",
abstract = "Background & Aims: N-linked glycosylation of proteins is critical for proper protein folding and trafficking to the plasma membrane. Drug transporters are one class of proteins that have reduced function when glycosylation is impaired. N-linked glycosylation of plasma proteins has also been investigated as a biomarker for several liver diseases, including non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to assess the transcriptomic expression of genes involved in protein processing and glycosylation, and to determine the glycosylation status of key drug transporters during human NAFLD progression. Methods: Human liver samples diagnosed as healthy, steatosis, and non-alcoholic steatohepatitis (NASH) were analysed for gene expression of glycosylation-related genes and for protein glycosylation using immunoblot. Results: Genes involved in protein processing in the ER and biosynthesis of N-glycans were significantly enriched for down-regulation in NAFLD progression. Included in the down regulated N-glycan biosynthesis category were genes involved in the oligosaccharyltransferase complex, N-glycan quality control, N-glycan precursor biosynthesis, N-glycan trimming to the core, and N-glycan extension from the core. N-glycan degradation genes were unaltered in the progression to NASH. Immunoblot analysis of the uptake transporters organic anion transporting polypeptide-1B1 (OATP1B1), OATP1B3, OATP2B1, and Sodium/Taurocholate Co-transporting Polypeptide (NTCP) and the efflux transporter multidrug resistance-associated protein 2 (MRP2) demonstrated a significant loss of glycosylation following the progression to NASH. Conclusions: These data suggest that the loss of glycosylation of key uptake and efflux transporters in humans NASH may influence transporter function and contribute to altered drug disposition observed in NASH.",
keywords = "drug transporters, hepatobiliary drug disposition, N-linked glycosylation, Non-alcoholic steatohepatitis",
author = "Clarke, {John D.} and Petr Novak and Lake, {April D.} and Hardwick, {Rhiannon N.} and Cherrington, {Nathan J}",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/liv.13362",
language = "English (US)",
volume = "37",
pages = "1074--1081",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease

AU - Clarke, John D.

AU - Novak, Petr

AU - Lake, April D.

AU - Hardwick, Rhiannon N.

AU - Cherrington, Nathan J

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background & Aims: N-linked glycosylation of proteins is critical for proper protein folding and trafficking to the plasma membrane. Drug transporters are one class of proteins that have reduced function when glycosylation is impaired. N-linked glycosylation of plasma proteins has also been investigated as a biomarker for several liver diseases, including non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to assess the transcriptomic expression of genes involved in protein processing and glycosylation, and to determine the glycosylation status of key drug transporters during human NAFLD progression. Methods: Human liver samples diagnosed as healthy, steatosis, and non-alcoholic steatohepatitis (NASH) were analysed for gene expression of glycosylation-related genes and for protein glycosylation using immunoblot. Results: Genes involved in protein processing in the ER and biosynthesis of N-glycans were significantly enriched for down-regulation in NAFLD progression. Included in the down regulated N-glycan biosynthesis category were genes involved in the oligosaccharyltransferase complex, N-glycan quality control, N-glycan precursor biosynthesis, N-glycan trimming to the core, and N-glycan extension from the core. N-glycan degradation genes were unaltered in the progression to NASH. Immunoblot analysis of the uptake transporters organic anion transporting polypeptide-1B1 (OATP1B1), OATP1B3, OATP2B1, and Sodium/Taurocholate Co-transporting Polypeptide (NTCP) and the efflux transporter multidrug resistance-associated protein 2 (MRP2) demonstrated a significant loss of glycosylation following the progression to NASH. Conclusions: These data suggest that the loss of glycosylation of key uptake and efflux transporters in humans NASH may influence transporter function and contribute to altered drug disposition observed in NASH.

AB - Background & Aims: N-linked glycosylation of proteins is critical for proper protein folding and trafficking to the plasma membrane. Drug transporters are one class of proteins that have reduced function when glycosylation is impaired. N-linked glycosylation of plasma proteins has also been investigated as a biomarker for several liver diseases, including non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to assess the transcriptomic expression of genes involved in protein processing and glycosylation, and to determine the glycosylation status of key drug transporters during human NAFLD progression. Methods: Human liver samples diagnosed as healthy, steatosis, and non-alcoholic steatohepatitis (NASH) were analysed for gene expression of glycosylation-related genes and for protein glycosylation using immunoblot. Results: Genes involved in protein processing in the ER and biosynthesis of N-glycans were significantly enriched for down-regulation in NAFLD progression. Included in the down regulated N-glycan biosynthesis category were genes involved in the oligosaccharyltransferase complex, N-glycan quality control, N-glycan precursor biosynthesis, N-glycan trimming to the core, and N-glycan extension from the core. N-glycan degradation genes were unaltered in the progression to NASH. Immunoblot analysis of the uptake transporters organic anion transporting polypeptide-1B1 (OATP1B1), OATP1B3, OATP2B1, and Sodium/Taurocholate Co-transporting Polypeptide (NTCP) and the efflux transporter multidrug resistance-associated protein 2 (MRP2) demonstrated a significant loss of glycosylation following the progression to NASH. Conclusions: These data suggest that the loss of glycosylation of key uptake and efflux transporters in humans NASH may influence transporter function and contribute to altered drug disposition observed in NASH.

KW - drug transporters

KW - hepatobiliary drug disposition

KW - N-linked glycosylation

KW - Non-alcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=85012965467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012965467&partnerID=8YFLogxK

U2 - 10.1111/liv.13362

DO - 10.1111/liv.13362

M3 - Article

VL - 37

SP - 1074

EP - 1081

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 7

ER -